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OBJECTIVE—Immune-mediated destruction of -cells result-
ing in type 1 diabetes involves activation of proinﬂammatory,
islet autoreactive T-cells, a process under the control of dendritic
cells of the innate immune system. We tested the hypothesis that
type 1 diabetes development is associated with disturbance of
blood dendritic cell subsets that could enhance islet-speciﬁc
autoimmunity.
RESEARCH DESIGN AND METHODS—We examined blood
dendritic cells (plasmacytoid and myeloid) in 40 patients with
recent-onset diabetes (median duration 28 days) and matched
control subjects. We also examined the relative ability of differ-
ent dendritic cell subsets to process and present soluble or
immune complexed islet cell autoantigen (the islet tyrosine
phosphatase IA-2) to responder CD4 T-cells.
RESULTS—The balance of blood dendritic cells was profoundly
disturbed at diabetes diagnosis, with a signiﬁcantly elevated
proportion of plasmacytoid and reduction of myeloid cells com-
pared with control subjects. Dendritic cell subset distribution
was normal in long-standing disease and in patients with type 2
diabetes. Both dendritic cell subsets processed and presented
soluble IA-2 to CD4 T-cells after short-term culture, but only
plasmacytoid dendritic cells enhanced (by as much as 100%)
autoantigen presentation in the presence of IA-2
 autoantibody
patient serum.
CONCLUSIONS—The plasmacytoid subset of dendritic cells is
overrepresented in the blood close to diabetes onset and shows
a distinctive ability to capture islet autoantigenic immune com-
plexes and enhance autoantigen-driven CD4 T-cell activation.
This suggests a synergistic proinﬂammatory role for plasmacy-
toid dendritic cells and islet cell autoantibodies in type 1 diabe-
tes. Diabetes 58:138–145, 2009
T
ype 1 diabetes is an autoimmune disease result-
ing from T-cell–mediated destruction of insulin-
producing -cells (1–3). Although the precise
aetiopathogenesis of the disease is unknown, it
is apparent that -cell damage involves the generation of
activated, proinﬂammatory, islet-autoreactive, effector
CD4 and CD8 T-cells (3,4). The priming, differentiation,
and expansion of effector T-cells is largely under the
control of a heterogeneous group of immune cells that go
under the collective term of dendritic cells, because of
their distinctive morphology (5). Dendritic cells have
numerous specialized forms present in peripheral tissues,
lymph nodes, and the blood, and collectively, these cells
are responsible for the sensing and ingestion of pathogens
and activation of T-cells of relevant speciﬁcity. Because
activated dendritic cells are a requirement for priming of
naïve T-cells, it is likely that a similar process pertains
during the development of islet autoreactivity, although
the activating stimuli and islet autoantigens involved re-
main obscure. It is also likely that once this process is
initiated, dendritic cell presentation of islet autoantigens
remains a feature of the disease, because spreading of the
autoimmune response to additional autoantigens and
epitopes develops (6).
Given the pivotal role of dendritic cells in the activation
of naïve T-cells, there is a strong justiﬁcation for investi-
gating their activity in type 1 diabetes. Until relatively
recently, however, opportunities to study dendritic cells in
a human disease setting were limited. In recent years,
there has been an increasing recognition that two of the
major dendritic cell subsets, the myeloid (myeloid den-
dritic cell) and plasmacytoid (plasmacytoid dendritic cell)
forms are present at low levels in the circulation and can
be identiﬁed by their expression of distinct lineage and
functional markers (7,8). Plasmacytoid dendritic cells,
also known as the type I interferon (IFN)-producing cells,
are of particular interest, being specialized in the sensing
of virus infection through selective expression of Toll-like
receptors (TLRs) speciﬁc for viral single-stranded RNA
(TLR7) and double-stranded DNA (TLR9) (9). Ligation of
such viral receptors results in the rapid secretion of type I
IFNs, such as IFN-, at levels 100-1,000 times more than
any other cell type. Serum IFN- levels are elevated in
children at diagnosis of type 1 diabetes (10); IFN mRNA
subtypes are found in post mortem pancreas samples from
type 1 diabetic patients (11); and critically, IFN- treat-
From the
1Department of Immunobiology, King’s College London, School of
Medicine, London, U.K.; the
2Institute of Cell and Molecular Science, St
Bartholomew’s Hospital, London, U.K.; the
3Queen Elizabeth Hospital
National Health Service Trust, London, U.K.; the
4Henry Wellcome Labora-
tories for Integrative Neuroscience and Endocrinology, University of Bris-
tol, Bristol, U.K.; and the
5National Institute for Health Research Biomedical
Research Centre, Guy’s & St. Thomas’ National Health Service Foundation
Trust and King’s College London, U.K.
Corresponding author: Mark Peakman, mark.peakman@kcl.ac.uk.
Received 17 July 2008 and accepted 18 September 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 3 October
2008. DOI: 10.2337/db08-0964.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
See accompanying commentary, p. 12.
ORIGINAL ARTICLE
138 DIABETES, VOL. 58, JANUARY 2009ment for diseases such as chronic viral hepatitis and
cancer has precipitated the clinical manifestation of auto-
immune disease, including type 1 diabetes, in a number of
cases (12,13). Moreover, there is emerging evidence of a
close relationship between plasmacytoid dendritic cells,
excessive amounts of type I IFNs, and other autoimmune
conditions (14).
We hypothesized that the existence of a relationship
between type I IFNs and type 1 diabetes close to the onset
of the disease might be reﬂected in a disturbance in blood
dendritic cell subsets. Our study demonstrates a profound
disturbance in the normal balance of plasmacytoid den-
dritic cells and myeloid dendritic cells in peripheral blood
in the immediate period after diagnosis. Moreover, we
show that plasmacytoid dendritic cells capture islet cell
autoantigens via immune complexes and in so doing
enhance CD4 T-cell activation, suggesting synergy be-
tween elements of the innate and adaptive immune sys-
tems, and islet cell autoantibodies in particular, in type 1
diabetes–related autoimmunity.
RESEARCH DESIGN AND METHODS
For dendritic cell enumeration studies, fresh heparinized blood was obtained
from 40 patients with new-onset type 1 diabetes (mean age 27  7.2 years;
disease duration 30  15 days) and 40 nondiabetic control subjects of similar
age, sex, and HLA type with no family history of autoimmune disease (mean
age 29  5.2 years). Eighteen patients with long-standing type 1 diabetes
(median disease duration 19.5 years, range 3–58 years; mean age 44  13.8
years) were also studied along with an additional, appropriately matched
nondiabetic control group (n  18; mean age 34  10 years). In addition, 16
patients with type 2 diabetes (median disease duration 7.5 years, range 2–16
years, mean age 59.8  11.7 years) were also studied along with an appropri-
ately matched nondiabetic control group (n  16; mean age 51  8.7 years).
Blood was also obtained from a further group of patients with new-onset type
1 diabetes and from control subjects of similar age, sex, and HLA-type for
detailed analysis of dendritic cell phenotype (n  13 in each group) and
dendritic cell cytokine production after in vitro stimulation (n  9 in each
group). All type 1 diabetic patients gave a history of acute onset of symptoms
typical of diabetes and required insulin from diagnosis. Typically, blood from
a patient was analyzed alongside that of an appropriate control taken at the
same time of day to avoid any potential confounding effects of diurnal rhythm
and season. Patients or control subjects reporting recent (up to 2 weeks)
symptoms of “virus-like” illnesses were excluded from participation in the
study. Metabolic control was assessed by measurement of A1C at the time of
blood sampling for dendritic cell studies. The presence of autoantibodies to
IA-2 and glutamic acid decarboxylase-65 (GAD65) was detected by radioim-
munoassay (RSR, Cardiff, U.K.).
Dendritic cell enumeration. Lysed whole blood direct immunoﬂuoresence
staining for the quantitation of dendritic cell subsets was performed using the
Blood DC Enumeration Kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Brieﬂy, 300 l whole blood was
incubated with either the anti-BDCA cocktail, containing monoclonal antibod-
ies (mAbs) speciﬁc for the dendritic cell markers BDCA-1 (CD1c for detecting
myeloid dendritic cell 1), BDCA-2 (CD303 for detecting plasmacytoid den-
dritic cells), and BDCA-3 (CD141 for detecting myeloid dendritic cell 2);
anti-CD14 (monocytes); and anti-CD19 (B-cells) or the control cocktail
(containing appropriate isotype control mAbs). After 10-min photoincubation
with these and a dead cell discriminator on ice, erythrocytes were lysed, and
remaining cells were washed in PBS containing 1% BSA (Sigma-Aldrich, Poole,
U.K.), 0.1% sodium azide, 2% FCS (Invitrogen, Paisley, U.K.), and 1% human AB
serum (PAA, Linz, Austria) (ﬂow buffer). Cells were ﬁxed and analyzed by
four-color ﬂow cytometry using a FACSCalibur cytometer (BD Biosciences,
San Jose, CA). CD14
, CD19
, and dead cells were excluded, and dendritic
cell subsets were enumerated. A minimum of 3.5  10
5 events in the
mononuclear (forward and side scatter) gate were collected, of which a mean
of 0.8% are dendritic cells (2,800 events). Gates denoting positivity for
markers of myeloid dendritic cell 1, myeloid dendritic cell 2, and plasmacytoid
dendritic cell were set using the appropriate isotype control mAbs and the
number of dendritic cells in a sample expressed as a percentage of the total
number of gated mononuclear cells or the total number of dendritic cells.
Dendritic cell isolation, phenotypic analysis, and stimulation. Periph-
eral blood mononuclear cells (PBMCs) were obtained from whole blood by
density gradient centrifugation (Lymphoprep; Axis Shield, Dundee, U.K.).
CD14
 and CD19
 cells were depleted from PBMCs using magnetic cell
sorting technology (AutoMACS; Miltenyi Biotech). Myeloid dendritic cells
were then positively isolated from the remaining PBMCs using BDCA-1
–
conjugated magnetic microbeads and plasmacytoid dendritic cells then iso-
lated from the remaining cells using BDCA-4
–conjugated magnetic
microbeads. Averaging from 20 separations, mean  SD purity was 78.8 
10.9% for plasmacytoid dendritic cells and 75.0  19.5% for myeloid dendritic
cells.
Markers of activation and function were analyzed by four-color ﬂow
cytometry using 2  10
4 dendritic cells in 100 l ﬂuorescence-activated cell
sorting buffer along with the appropriate ﬂuorochrome-labeled mAbs. Sam-
ples were incubated on ice in the dark for 30 min and then washed twice in
ice-cold ﬂow buffer before immediate analysis. The following mAbs were
used: ﬂuorescein isothiocyanate–labeled anti-CD19 (clone LT19), anti–HLA-
ABC (clone W6/32), and anti-CD83 (clone HB15e) mAbs; phycoerythrin
(PE)-labeled anti-CD62L (clone FMC46) and anti-CD80 (clone MEM-233)
mAbs (all from Serotec, Oxford, U.K.); PE-labeled anti-CD4 (clone RPA-T4),
peridinin chlorophyll protein–labeled anti-CD14 (clone M	 P9), and anti–
HLA-DR (clone TU36) mAbs; and allophycocyanin-labeled anti-CD3 (clone
UCHT1), anti-CD86 (clone 2331FUN-1) (all BD Pharmingen, San Diego, CA),
and anti-CD123 (clone AC145) mAbs (Miltenyi Biotec). Antibody concentra-
tions used were based on data supplied by the manufacturers and in-house
optimization studies. For these studies, the selected dendritic cell subset was
always gated using a speciﬁc marker (BDCA1 for myeloid dendritic cell and
CD123 for plasmacytoid dendritic cell). Gated cells were then assessed for the
mean ﬂuorescence intensity of the speciﬁc activation/maturation marker.
In studies on the cytokine potential of isolated blood dendritic cell subsets,
myeloid dendritic cells and plasmacytoid dendritic cells were resuspended to
2  10
5 per ml in RPMI 1640 supplemented with penicillin, streptomycin, and
fungizone (Invitrogen) and 10% human AB serum. Myeloid dendritic cells were
stimulated with lipopolysaccharide (Sigma-Aldrich) at concentrations of 0 and
10 ng/ml in a total volume of 200 l in duplicate samples. Plasmacytoid
dendritic cells underwent similar treatment in cultures supplemented with 10
ng/ml recombinant human interleukin (IL)-3 (Strathmann Biotec, Hamburg,
Germany) and were stimulated with unmethylated oligodeoxynucleotides
(ODN 2216, a potent TLR-9 ligand and IFN- secretagog; Autogen Bioclear,
Calne, U.K.) at concentrations of 0, 1, 3, 10, and 30 g/ml in a total volume of
200 l in duplicate samples (15,16). After 16 h of stimulation, supernatants
were collected and stored at 
80°C for later analysis. IFN- production in
plasmacytoid dendritic cell culture supernatants was quantiﬁed by speciﬁc
sandwich ELISA using the IFN- module set (detection range 8–5,000 pg/ml;
Bender MedSystems). There are 14 different IFN- isoforms, of which the
IFN- module set detects the majority, with the exception of B and F.
Supernatants from myeloid dendritic cell and plasmacytoid dendritic cell
cultures were analyzed using the Beadlyte Human Cytokine Detection kit 3
(Upstate, Lake Placid, NY) according to the manufacturer’s instructions.
Cytokines IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, Il-12p70, tumor necrosis factor-
(TNF-), and IFN- were measured (detection range 6.9–5,000 pg/ml). Data
were analyzed on the Luminex 100 instrument system using STarstation
software.
Presentation of autoantigens by dendritic cells. cDNA encoding human
IA2-intracellular portion (IA-2ic) was modiﬁed to include a coding sequence
for the HLA-DR4 restricted inﬂuenza hemagglutinin CD4 T-cell epitope
(HA307–319), inserted at the NH2-terminus of IA-2ic, and recombinant IA-2ic-
HA307–319 protein was prepared as described previously (17,18). An HLA-DR4
restricted CD4 T-cell clone speciﬁc for HA307–319 (JNZ-1) was generated by
peptide stimulation of PBMC cultures, followed by ﬂow cytometric sorting of
cells stained positive with an HLA-DR4 tetramer loaded with HA307–319
(provided by Dr. G. Nepom, Benaroya Research Institute, Seattle, WA).
Plasmacytoid dendritic cells, myeloid dendritic cells, and CD14
 monocytes
were isolated from HLA-DR4
 subjects and resuspended to 5  10
4/ml, and
100 l was dispensed into 96-well ﬂat-bottomed plates in serum-free X-VIVO
15 (Cambrex, Charles City, IA). Cultures were supplemented with serum from
type 1 diabetic patients positive for either IA-2 or GAD65 autoantibodies, or
pooled AB (1–30%) and IA-2ic-HA307–319 (10 g/ml). In some experiments, the
IgG fraction in IA-2
 autoantibody serum was depleted by incubation with
protein A matrix (binding capacity 18–43 mg/ml; Repligen, Waltham, MA) at
a 1:1 ratio for 90 min at room temperature according to the manufacturer’s
instructions. After centrifugation (15 s at 10,000g), unbound serum was
carefully removed, and IgG depletion was conﬁrmed by laser nephelometric
analysis of IgG levels on samples before and after adsorption. After 24 h of
dendritic cell culture with serum under these conditions, JNZ-1 clone cells
(10
5/well) were added, and 48 h later, IFN- levels in supernatants were
quantiﬁed by ELISA (detection range 2–500 pg/ml; Immunotools, Friesoythe,
Germany).
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total dendritic cells, were normally distributed in all study groups according to
Kolmogorov-Smirnov analysis. Mean levels of dendritic cell subsets were
therefore compared between study groups using the Student’s t test. Relation-
ships between dendritic cell subset numbers and clinical parameters were
compared by calculation of Pearson’s correlation coefﬁcient. Differences in
distribution were compared by 
2 analysis. P values of 
0.05 were considered
signiﬁcant. Differences in IFN- production were compared using Student’s t
tests.
RESULTS
Detection of dendritic cell subsets in whole blood.
Dendritic cell subsets were identiﬁed in whole blood using
speciﬁc mAbs among mononuclear cells identiﬁed by their
physical side and forward scatter properties (Fig. 1A) after
removal of CD14
, CD19
, and dead cells by exclusion
gating (Fig. 1B). Dendritic cell numbers were expressed as
a percentage of mononuclear cells and dendritic cell
subsets as a proportion of total dendritic cells. Represen-
tative examples of BDCA-1
 (myeloid dendritic cells),
BDCA-2
 (plasmacytoid dendritic cells), and BDCA-3

(myeloid dendritic cell 2) cells are shown in Fig. 1C–E. The
majority of events in the CD14

/CD19

 gate in Fig. 1B are
T-cells, with some natural killer and natural killer T-cells.
The relative proportion of this population was not different
between type 1 diabetic patients and control subjects
(data not shown).
Dendritic cell subsets in type 1 diabetic patients. The
total number of dendritic cells (i.e., cells expressing
BDCA-1, BDCA-2, or BDCA-3) when expressed as a per-
centage of the total mononuclear cell population was
similar in new-onset type 1 diabetic patients and nondia-
betic control subjects (Fig. 1F).
However, within the total dendritic cell population,
dendritic cell subsets had a different proportional distri-
bution in the two study groups. The mean percentage of
dendritic cells belonging to the plasmacytoid dendritic cell
subset was signiﬁcantly higher in new-onset type 1 dia-
betic patients when compared with nondiabetic control
subjects (P  0.002; Fig. 2A). In contrast, the mean
percentage of myeloid dendritic cells was signiﬁcantly
lower in new-onset type 1 diabetic patients compared with
the nondiabetic control group (P  0.003; Fig. 2B). These
ﬁndings were similar regardless of whether dendritic cell
subsets were expressed as a percentage of total dendritic
cells or of mononuclear cells. There was no difference
between the study groups in the proportion of dendritic
cells belonging to the BDCA3
 myeloid dendritic cell 2
populations (Fig. 2C). Among the new-onset group, there
was no correlation between percentages of dendritic cell
subsets and age or duration of diabetes or A1C levels as a
marker of metabolic control. The percentage levels of
dendritic cell subsets were not different between patients
with and without islet cell autoantibodies and did not
differ between patient subgroups divided according to
HLA class II genotype.
To assess whether the abnormalities in dendritic cell
subsets observed in new-onset type 1 diabetic patients
could be genetically determined, we also studied pa-
tients in whom type 1 diabetes had been diagnosed for
a minimum of 3 years (median duration of disease 19.5
years, maximum 58 years). In these patients, mean
levels of total dendritic cells as a percentage of mono-
nuclear cells and the distribution of dendritic cell
subsets were similar to those in age-matched non-
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FIG. 1. Example of ﬂow cytometry analysis and gating strategy for identiﬁcation and quantiﬁcation of blood dendritic cell subsets. The
mononuclear cell population in whole blood is identiﬁed by a combination of forward and side scatter properties (A) followed by exclusion gating
of live CD14
 and CD19
 mononuclear cells and dead cells (B), before the identiﬁcation and enumeration of plasmacytoid dendritic cell (pDC),
myeloid dendritic cell 1 (mDC1), and myeloid dendritic cell 2 (mDC2) subsets, as shown in C–E with the relevant blood dendritic cell (BDC)
marker. F: Total dendritic cell populations as a percentage of mononuclear cells in 40 patients with new-onset type 1 diabetes and matched
control subjects. (Please see http://dx.doi.org/10.2337/db08-0964 for a high-quality digital representation of this ﬁgure.)
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140 DIABETES, VOL. 58, JANUARY 2009diabetic control subjects (Fig. 3A–D). We also examined
the potential inﬂuence of hyperglycemia per se on
dendritic cell subsets by analysis of patients with type 2
diabetes with similar levels of A1C (mean  SD 7.9 
1.9%) compared with the new-onset patients (8.73 
2.1%; NS). Chronic hyperglycemia alone could not ac-
count for the changes we observed, because propor-
tions of dendritic cell subsets did not differ signiﬁcantly
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FIG. 2. Dendritic cell subsets in new-onset type 1 diabetic patients and control subjects showing plasmacytoid dendritic cells (A), type 1 myeloid
dendritic cells (B), and type 2 myeloid dendritic cells (C). Results are expressed as percentage of total dendritic cell population. Mean values
for each group are indicated by a horizontal line, and P values are given where signiﬁcant.
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FIG. 3. Dendritic cell subsets in long-standing type 1 diabetic patients (LS T1D) and age-matched control subjects showing total dendritic cell
population as a percentage of mononuclear cells (A) and the plasmacytoid dendritic cell (B), type 1 myeloid dendritic cell (C), and type 2 myeloid
dendritic cell (D) subsets as a percentage of total dendritic cells. Mean values for each group are indicated by a horizontal line and were similar
between study groups. Similarly, E–G show plasmacytoid dendritic cell (E), type 1 myeloid dendritic cell (F), and type 2 myeloid dendritic cell
(G) subsets as a percentage of total dendritic cells in patients with type 2 diabetes and an appropriately age-matched control group. Mean levels
are similar in the two groups (NS).
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subjects (Fig. 3E–G).
Although the populations of patients with type 1 diabe-
tes (new-onset and long-standing) were not closely age-
matched, we also compared the distribution of dendritic
cell subsets between them; this comparison seemed justi-
ﬁed in the absence of any relationship between age and
dendritic cell subset number in the patient and control
subject groups. Mean levels of plasmacytoid dendritic
cells were higher, and mean levels of myeloid dendritic
cells were lower in the new-onset patients (P  0.0013 and
0.0014, respectively). These data suggested that dendritic
cell subset balance is disturbed near to disease diagnosis
but gradually normalizes. Further evidence for this was
obtained by repeat analysis of blood samples on ﬁve
patients tested both at diagnosis and 2 years later. Three of
the ﬁve show evidence of declining plasmacytoid dendritic
cell percentages, and four had increased/unchanged per-
centages of myeloid dendritic cells at year 2 (Fig. 4A and
B), although with small numbers of subjects, these can
only be considered indicative trends (NS). This contrasts
with data from a control individual analyzed seven times
over the same 2-year period, in whom plasmacytoid den-
dritic cell and myeloid dendritic cell subsets were remark-
ably stable (Fig. 4C). Taken together, these data indicate
that type 1 diabetes is characterized by an abnormal
distribution of dendritic cells, resulting in high levels of
plasmacytoid dendritic cells and low levels of myeloid
dendritic cells but that these changes are restricted to the
peri-diagnosis period.
Expression of differentiation and activation markers
on plasmacytoid dendritic cells and myeloid dendritic
cells in type 1 diabetic patients. Because the plasma-
cytoid dendritic cell population appeared to be expanded
at diagnosis of type 1 diabetes, we next wished to deter-
mine whether this expansion was associated with activa-
tion of this subset. Blood plasmacytoid dendritic cells
expressed high basal levels of HLA molecules (both class
I and class II), IL-3 receptor (CD123), and L-selectin
(CD62L) but low levels of the dendritic cell activation
marker CD83 and the costimulatory molecules CD80 and
CD86, which are typically upregulated on activation. My-
eloid dendritic cells were also found to express high levels
of HLA class I and class II molecules. Myeloid dendritic
cells also expressed detectable levels of CD83, CD80, and
CD86 but without any sign of upregulation of these acti-
vation molecules in patients (supplementary Fig. 1, avail-
able in an online appendix at http://dx.doi.org/10.2337/
db08-0964). Formal comparison of the levels of expression
of these markers in new-onset type 1 diabetic patients and
nondiabetic control subjects (n  13 in each group) failed
to show any signiﬁcant differences.
Cytokine and chemokine production by plasmacytoid
dendritic cells and myeloid dendritic cells. Plasmacytoid
dendritic cells are capable of producing very large quantities
of type I IFNs after stimulation; and to assess their IFN-–
producing capacity in type 1 diabetes, cells isolated from the
study groups were cultured with a TLR9 ligand, and IFN-
secretion was measured. Plasmacytoid dendritic cells from
both new-onset type 1 diabetic patients and nondiabetic
control subjects (n  9 in each group) did not produce IFN-
without stimulation. After stimulation with CpG oligonucle-
otide, plasmacytoid dendritic cells from patients and control
subjects produced similar, large amounts of IFN- in a
dose-dependent manner (Fig. 5). Thus, per-plasmacytoid
dendritic cell IFN- secretion is not abnormal in patients,
and there is no evidence of spontaneous ex vivo IFN-
secretion by these cells, making it unlikely that they are the
source of the elevated serum levels of this cytokine that
has been reported in type 1 diabetic patients (10). Using
the same samples, we also examined basal and stimulated
secretion of IL-1, IL-6, IL-8, IL-10, IL-12p70, TNF-, and
IFN- by plasmacytoid dendritic cells and myeloid dendritic
cells. No differences between patients and control subjects
were observed.
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FIG. 4. Plasmacytoid (A) and myeloid (B) dendritic cell subsets as a percentage of total dendritic cells in ﬁve patients with new-onset type 1
diabetes measured at diagnosis and 2 years later. There is a trend in three of the patients for plasmacytoid dendritic cell levels to decline and
in three of the patients for myeloid dendritic cell levels to increase/remain unchanged. C: Dendritic cell subset levels (expressed as a percentage
of dendritic cells) in a nondiabetic control individual studied on seven separate occasions over the same 2-year period.
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FIG. 5. IFN- secretion by isolated plasmacytoid dendritic cells in type
1 diabetic patients and control subjects in response to stimulation with
increasing concentrations of the unmethylated CpG oligonucleotide
2,216. Each point represents the mean value of IFN- secretion from
nine different patients (Œ) and nine control subjects (). Vertical bars
represent SEs.
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toantigen presentation to plasmacytoid dendritic cells.
It has recently been reported that plasmacytoid den-
dritic cell presentation of antigen is enhanced in the
presence of immune complexes containing the relevant
antigen (19). We designed experiments in which plas-
macytoid dendritic cells, myeloid dendritic cells, and
monocytes presented a hybrid construct of IA-2ic con-
taining the inﬂuenza hemagglutinin epitope HA307–319.
Activation of an HA307–319-speciﬁc CD4 T-cell clone
(JNZ-1) was used as the measure of efﬁciency of IA-2ic-
HA307–319 presentation. Serum positive or negative
for IA-2 autoantibodies was then added to examine
whether presentation was enhanced in the presence of
relevant autoantibody speciﬁcities. Presentation of IA-
2ic-HA307–319 by plasmacytoid dendritic cells was en-
hanced in the presence of serum containing IA-2, but not
GAD65, autoantibodies (Fig. 6A). IFN- production by
the T-cell clone was more than doubled in the presence
of IA-2 autoantibodies (P 
 0.05 compared with control
serum for 5 and 10% serum supplementation). In con-
trast, myeloid dendritic cell and monocyte presentation
of IA-2ic-HA307–319 was largely unaffected by the pres-
ence of islet cell autoantibodies (Fig. 6B and C). In the
case of myeloid dendritic cells, it is probable that their
uptake and presentation of antigen through pinocytosis
is highly efﬁcient in the absence of immune complexes
and therefore not enhanced to any great degree in their
presence.
The effect of IA-2
 serum samples in enhancing antigen
presentation of IA-2ic-HA307–319 was seen in samples from
more than one patient with IA-2 autoantibodies and was
highly signiﬁcant (Fig. 6D and E). The enhancing effect
was attributable to the IgG fraction in the serum samples,
because it was signiﬁcantly diminished after IgG depletion
using a protein A-Sepharose column (Fig. 6F). Enhanced
presentation of IA-2 by plasmacytoid dendritic cells was
not associated with IFN- production.
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FIG. 6. Effect of islet cell autoantibody–positive serum on presentation by plasmacytoid dendritic cells (A), myeloid dendritic cells (B), and
CD14
 monocytes (C) of the islet cell autoantigen IA-2ic-HA307–319 to CD4 T-cells (JNZ-1 clone) speciﬁc for the inﬂuenza HA307–319 epitope. CD4
T-cell clone responses are indicated by levels of IFN- produced in the culture supernatants. A: In the presence of soluble 10 g/ml
IA-2ic-HA307–319 without serum supplementation (), IA-2ic is processed and presented with comparable efﬁciency by plasmacytoid dendritic
cells and myeloid dendritic cells, with CD14
 monocytes markedly less proﬁcient. Addition of IA-2
 autoantibody (AAb) serum (3,500 World
Health Organization [WHO] units) at 1, 5, and 10% (f) considerably and signiﬁcantly enhances the presentation of IA-2ic by plasmacytoid
dendritic cells but has minimal effects on myeloid dendritic cells and CD14
 monocytes (*P < 0.05 vs. presence of antigen alone; ). GAD65

autoantibody serum (1,700 WHO units; u; 1–10%) has no effect on presentation. Likewise, pooled AB serum at these concentrations has no effect
(data not shown). In the presence of 5% serum but no IA-2ic-HA307–319, there is no T-cell activation. Data represent one of four experiments using
four different cell donors. D: Pooled data from a total of four donors (including the one used in A) for plasmacytoid dendritic cell enhancement
of IA-2ic-HA307–319 (f) presentation to JNZ-1 clone cells (*P < 0.05, **P < 0.01, and ***P < 0.001 vs. presence of antigen alone; ). The additional
sera contained 3,875.1, 3,263.1, and 3,007.8 WHO units of IA-2 autoantibodies. Bars represent means  SE from quadruplicate wells of individual
experiments. E: IA-2
 serum–enhanced IA-2ic-HA307–319 presentation is dependent on the serum IgG fraction. Serum has been adsorbed using
Protein A matrix. Serum IgG level before adsorption, 6.54 g/l; after adsorption, 0.22 g/l. Serum was used at 5% concentration in these
experiments. Serum IA-2 autoantibody level before adsorption, 2,152 WHO units; after adsorption, IA-2 autoantibodies were not detectable.
*Signiﬁcant reduction in IFN- production by clone JNZ-1 in the presence of adsorbed compared with nonadsorbed serum (P < 0.05).
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Our study shows an abnormal distribution of the main
blood dendritic cell subsets in type 1 diabetes. IFN-
producing plasmacytoid dendritic cells, rather than my-
eloid dendritic cells, predominate proportionally among
dendritic cells in type 1 diabetic patients, and because
these changes were only observed at diagnosis of disease,
it seems unlikely that the alterations are genetically deter-
mined. The increased proportion of plasmacytoid den-
dritic cells and reduction in myeloid dendritic cells was
not accompanied by changes in activation status of these
cells, nor, in the case of plasmacytoid dendritic cells, by a
change in their capacity for IFN- secretion. There is no
immediate explanation for this increased representation of
plasmacytoid dendritic cells, but taken together with pre-
vious reports of abnormal levels of circulating and tissue-
deposited type I IFNs in type 1 diabetes, these ﬁndings
extend the concept of a relationship between type I IFNs,
their major cellular source the plasmacytoid dendritic cell,
and the onset of type 1 diabetes. Further weight is given to
the potential importance of this relationship by our dem-
onstration that plasmacytoid dendritic cells have en-
hanced ability to activate primed effector CD4 T-cells in
the presence of islet cell autoantibodies, indicating a route
through which autoantibodies could promote cell-medi-
ated islet autoimmunity.
Reagents for the reliable detection of dendritic cell
subsets in peripheral blood have only recently become
available, and few investigators have yet had the opportu-
nity to deploy this technology in autoimmune diseases. To
the best of our knowledge, this is the ﬁrst study to
demonstrate an increase in plasmacytoid dendritic cells in
new-onset type 1 diabetic patients using this approach.
These ﬁndings are similar to those in the preliminary
report of Peng et al. (20), who did not use the BDCA
dendritic cell markers but rather detected plasmacytoid
dendritic cells as lineage-negative/HLA-DR
/CD11c

/
CD123
 and myeloid dendritic cells as lineage-negative/
HLA-DR
/CD11c
/CD123

 cells. This group also found a
higher proportion of plasmacytoid dendritic cells in type 1
diabetes, although speciﬁc results are not reported, limit-
ing the opportunity for direct comparison. A more recent
report focuses on patients with type 1 diabetes of at least
5 years duration and ﬁnds no abnormality of blood den-
dritic cell balance, similar to our own analysis of long-
standing patients (21). In contrast, Vuckovic et al. (22)
have reported decreased dendritic cell numbers in chil-
dren with new-onset type 1 diabetes. However, these
authors did not use speciﬁc markers of dendritic cell
subsets, and they report levels of blood dendritic cells
(100 cells/l) that are vastly in excess of the known
concentration of these cells (1% of PBMCs, equivalent to
10–20 cells/l [7]).
Using an in vitro culture system, we show that in the
presence of islet cell autoantibodies of the relevant spec-
iﬁcity, the ability of plasmacytoid dendritic cells to pro-
cess and present islet autoantigens to CD4 T-cells is
signiﬁcantly enhanced. This immune complex capture is
known to operate through the Fc RII-receptor for IgG
(CD32), probably through enhanced antigen uptake (19).
Antibody-enhanced cross-presentation of an islet antigen
has also been shown to break tolerance in a murine model
of autoimmune diabetes (23). We consider it unlikely that
such a pathway is involved in the initial priming of islet
autoimmunity in man, but it could have an important role
in the ampliﬁcation and maintenance of T-cell responses
and also in epitope spreading (24). The ﬁnding that im-
mune complex capture by plasmacytoid dendritic cells
enhances autoreactive T-cell activation highlights a poten-
tial route through which autoantibodies could participate
in cell-mediated autoimmune responses, in addition to that
offered by B-cell presentation of autoantigens.
It is unclear why dendritic cell balance should be
perturbed near to diagnosis of type 1 diabetes, but our
studies exclude any possible effects of glycemic control.
One explanation is that selective migration of myeloid
dendritic cells into tissues or lymph nodes results in a
relative expansion of blood plasmacytoid dendritic cells,
especially if accompanied by proliferation of the dendritic
cell-precursor pool. The possible effect of dendritic cell
migration on blood levels has been noted in diseases in
which both inﬂamed tissues and the circulation have been
examined, such as psoriasis (25), systemic lupus erythem-
atosus (26), and respiratory syncytial virus infection (27),
each of which are associated with a reduction in plasma-
cytoid dendritic cells in peripheral blood and inﬁltration of
the tissues. An alternative hypothesis is that plasmacytoid
dendritic cell expansion occurs in response to a virus
infection that arises toward the end of the islet destructive
process. Virus infection at this late stage of disease is
known to be capable of accelerating disease onset in
animal models (28), and it is tempting to speculate that
this induces a shift in the ratio of plasmacytoid and
myeloid dendritic cells in the periphery.
At this stage, it is only possible to speculate on the
pathological relevance of our ﬁndings. Although the pos-
sibility of a proinﬂammatory role is attractive, studies in
animal models show that an increase in plasmacytoid
dendritic cell/myeloid dendritic cell ratio may prevent
antigen-speciﬁc inﬂammatory responses, including diabe-
tes (29–31), and a similar role in type 1 diabetes cannot be
excluded. Future studies that examine whether dendritic
cell subsets are disturbed in the pre-diabetic period and
therefore reﬂect events involved in the chronic autoim-
mune process of islet destruction or whether plasmacytoid
dendritic cell expansion is related solely to peri-diagnosis
events may clarify this.
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